GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Deep Medicine Acquisition Corp (NAS:DMAQ) » Definitions » EV-to-EBITDA

Deep Medicine Acquisition (Deep Medicine Acquisition) EV-to-EBITDA : -8.23 (As of May. 30, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Deep Medicine Acquisition EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Deep Medicine Acquisition's enterprise value is $15.74 Mil. Deep Medicine Acquisition's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.91 Mil. Therefore, Deep Medicine Acquisition's EV-to-EBITDA for today is -8.23.

The historical rank and industry rank for Deep Medicine Acquisition's EV-to-EBITDA or its related term are showing as below:

DMAQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1716.07   Med: 0   Max: 0
Current: -8.23

DMAQ's EV-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 9 vs DMAQ: -8.23

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-30), Deep Medicine Acquisition's stock price is $3.20. Deep Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.130. Therefore, Deep Medicine Acquisition's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Deep Medicine Acquisition EV-to-EBITDA Historical Data

The historical data trend for Deep Medicine Acquisition's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Deep Medicine Acquisition EV-to-EBITDA Chart

Deep Medicine Acquisition Annual Data
Trend Mar21 Mar22 Mar23
EV-to-EBITDA
- -396.68 -23.19

Deep Medicine Acquisition Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -126.99 -31.52 -23.19 -23.79 -27.61

Competitive Comparison of Deep Medicine Acquisition's EV-to-EBITDA

For the Shell Companies subindustry, Deep Medicine Acquisition's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deep Medicine Acquisition's EV-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Deep Medicine Acquisition's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Deep Medicine Acquisition's EV-to-EBITDA falls into.



Deep Medicine Acquisition EV-to-EBITDA Calculation

Deep Medicine Acquisition's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15.738/-1.912
=-8.23

Deep Medicine Acquisition's current Enterprise Value is $15.74 Mil.
Deep Medicine Acquisition's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deep Medicine Acquisition  (NAS:DMAQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Deep Medicine Acquisition's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.20/-0.130
=At Loss

Deep Medicine Acquisition's share price for today is $3.20.
Deep Medicine Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.130.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Deep Medicine Acquisition EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Deep Medicine Acquisition's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Deep Medicine Acquisition (Deep Medicine Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
595 Madison Avenue, 12th Floor, New York, NY, USA, 10017
Website
Deep Medicine Acquisition Corp is a blank check company.
Executives
John Chiang director 3538 TORRANCE BLVD., UNIT 177, TORRANCE CA 90503
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Humphrey P Polanen director, officer: Chief Executive Officer C/O HERITAGE COMMERCE CORP, 150 ALMADEN BLVD, SAN JOSE CA 95113
Weixuan Luo officer: Chief Financial Officer 40 WALL STREET, 29TH FLOOR, NEW YORK NY 10005
Marc Hamer director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Bright Vision Sponsor Llc 10 percent owner 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Ronald M. Razmi director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Hongliang Ren director 7951 S.W. 6TH STREET, SUITE 216, PLANTATION FL 33324
Wanlei Miao director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017
Tina Spires director 595 MADISON AVENUE, 12TH FLOOR, NEW YORK NY 10017

Deep Medicine Acquisition (Deep Medicine Acquisition) Headlines

From GuruFocus

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By GlobeNewswire GlobeNewswire 10-24-2022

Deep Medicine Acquisition Corp. Announces Appointment of a New Director

By Value_Insider Value_Insider 10-24-2022